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. The complex immune response after airborne transmission of the causative agent Mycobacterium tuberculosis and during progressive disease remains poorly characterized and understood 2, 3 . Confirmation of active TB is based on the combination of signs, symptoms and pathology (identified radiographically or histologically), as well as microbiological evidence of infection in sputum, typically by culture, which can take up to 6 weeks, and/or a nucleic-acid-amplification test 1, 4 ( Table 1) . However, it can be hard to obtain sputum samples from patients, and although bronchoalveolar lavage can be used as a substitute, this is prohibitive in countries with limited resources and is difficult in children 4, 5 . Furthermore, M. tuberculosis can disseminate from the lungs and cause disease throughout the body. Thus, alternative tests are needed to improve and support the diagnosis of TB.
It is estimated that one fourth of all people worldwide have been infected by M. tuberculosis. The majority of infected people generate an effective immune response to possibly eliminate or control the infection and remain clinically asymptomatic; this state is called 'latent TB infection' (LTBI) and is not transmissible. However, small proportion (about 5-15%) of people with latent TB go on to develop active TB disease at some stage during their lifetime 1 . However, multiple longitudinal epidemiological studies have demonstrated that the active TB disease in most people manifests soon after infection and that it is rare for disease to occur more than 2 years after infection, as has been revisited and discussed at length in a published review 6 . The current process of diagnosing LTBI involves assessing reactivity to mycobacterial antigens, as determined by a tuberculin skin test or an M. tuberculosis-specific interferon-γ (IFN-γ )-release assay (IGRA), which can demonstrate whether a T cell-mediated immune response has been elicited in response to the infection 7 , but both tests have poor prognostic value. These tests cannot determine whether the infection has been cleared, whether the person is controlling the infection or might have subclinical disease, or whether the person will go on to develop active TB (Fig. 1) . Thus, these methods incompletely capture the spectrum of infectious states observed after exposure to M. tuberculosis.
The heterogeneity of LTBI was recognized by epidemiological differences between recent infection and remote infection in terms of the risk of TB 8 . In a cohort of 35 asymptomatic people with LTBI and co-infection with human immunodeficiency virus type 1 (HIV-1), combined positron-emission and computed tomography identified ten people with pulmonary abnormalities suggestive of subclinical active disease who were much more likely to progress to clinical disease 9 . Such findings challenge the classic view that divides TB into two states (latent infection or active disease) and advocate the identification of biomarkers predictive of progression 9 . Progression from LTBI to active TB disease can be clinically subtle, and people with subclinical TB have been reported to transmit the organism to others 10 . Earlier identification of active TB in people with undiagnosed disease is needed to initiate the early treatment essential for limiting onward transmission. A means of screening high-risk populations to identify people with early disease or those with latent infection at high risk of developing TB is essential for the early application of prophylactic therapy to prevent TB.
The dynamic relationships that exist between the proposed states of latent TB or subclinical TB and immune factors that influence possible transition between states are not known. Although protective factors have been described, including the cytokines IL-12, IFN-γ and TNF, understanding of the early phase of infection with M. tuberculosis or progression to disease in humans is very limited 2, [11] [12] [13] [14] [15] [16] . The risk factors responsible for a large proportion of the cases of TB in the general population 3 include co-infection with HIV 17 , therapy with antibody to TNF 16, 18 , vitamin D deficiency 19 , protein-energy malnutrition 20 , pregnancy 21 and intercurrent viral infections 22, 23 . Better understanding of the early immune response to infection with M. tuberculosis in people who control the infection after recent contact, remain subclinical or go on to develop disease would greatly advance the development of improved diagnostics. PersPective | FOCUS NaTure ImmuNology
Blood transcriptomics elucidate the host response in TB
Blood transcriptomic profiling has provided an unbiased analysis and comprehensive overview of the host factors that are perturbed after infection and during active TB. A transcriptional signature dominated by interferon-inducible genes was identified in the whole blood of patients with active TB but not in that of healthy control subjects or the majority of people with LTBI 24 . This interferon-inducible gene signature included genes downstream of both IFN-γ and type I interferons and was diminished in expression after successful treatment 24, 25 . This transcriptomic signature has been confirmed in several studies worldwide with independent clinical cohorts [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and in meta-analyses combining several of those cohorts [36] [37] [38] [39] . An underabundance of a type II interferon (IFN-γ ) response in the transcriptional blood signature of patients with TB, with downregulation of IFNG (which encodes IFN-γ ) and TBX21 (which encodes the transcription factor T-bet), has also been found 39 . Type I interferons have a deleterious effect on the control of TB in mouse models 2, 22, [40] [41] [42] [43] [44] [45] [46] , consistent with a correlation between an interferon-inducible transcriptional signature in the blood and radiographic evidence of lung disease in human TB 24 and in non-human primate models 47 . The production of type I interferons by macrophages infected with different strains of M. tuberculosis can result from differential activation of the pattern-recognition receptors TLR2 or TLR4, the latter of which induces the downstream adaptor TRIF 48 . The cytosolic-DNA sensor cGAS has a central role in the detection of mycobacterial DNA [49] [50] [51] or mitochondrial DNA 52 released into the host cytosol and in the induction of the transcription of genes encoding type I interferons in macrophages. Although M. tuberculosis can induce type I interferons in macrophages via these diverse pathways, various studies have shown that an elevated abundance of type I interferons 23, [40] [41] [42] [43] [44] 46, 53, 54 , resulting from virulent strains of M. tuberculosis 41, 42, 48 , genetic deletion of type I interferon-regulatory genes such as tpl-2 44 or adjuvant 43, 54 or viral co-infection 23 , is needed to induce detrimental effects in the host after infection with M. tuberculosis (Fig. 2) . Large amounts of type I interferons can result from differences in the host genetic background [40] [41] [42] 55 , the dose or strain of mycobacteria in the challenge 41, 42, 48 or the composition of the microbiome 56, 57 (all reviewed in ref.
2
). An association between impaired signaling via type I interferons and increased resistance to TB has been reported 58 
.
Patients with an inherited deficiency in the gene encoding the ubiquitin-like modifier ISG15 (encoded by an interferon-stimulated gene) 59 are more susceptible to mycobacterial infection 60 , although there is 
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NaTure ImmuNology some debate as to whether it is the increase in type I interferons that is responsible for the susceptibility to TB. Various mechanisms account for the adverse effects of type I interferons in TB (reviewed in ref. 45 ), including inhibition of IL-1 and prostaglandin E 2 , which are critical for the defense against infection with M. tuberculosis 43, 53, 61, 62 . The adverse effects of type I interferons on TB might be explained by the induction of IL-10, which suppresses the production of proinflammatory cytokines required for the control of TB 53, 63 . The elevated abundance of IL-10 observed in mouse models of TB and human disease 2 contributes to increased bacterial loads 2, 13, [64] [65] [66] . We are tempted to speculate that blockade of signaling via the receptor for IFN-α and IFN-β , which is currently in clinical trials for autoimmunity 67 , could be applied in conjunction with anti-mycobacterial drugs to reduce the high expression of type I interferons for the treatment of TB, especially in people with very severe disease and/or multi-drug resistance TB. The use of biologics as immunomodulators is supported by findings that people with mutations in IL12RB (which encodes a subunit of the receptor for IL-12) or IFNG 15 have been successfully treated with anti-mycobacterial drugs, in combination with either IL-12 or IFN-γ , respectively.
In some cases, type I interferons might provide protection against mycobacterial diseases 68, 69 , indicative of context specificity in the pathogenesis of TB 45 . Small amounts of type I interferons are required for the production of IL-12 and TNF 53 , which suggests that small amounts of type I interferons might be protective against TB in the context of a low burden of M. tuberculosis. Conversely, high and sustained signaling via type I interferons, potentially resulting from various genetic or context-specific effects, including co-infection, might contribute to the pathogenesis of TB, in part through the induction of IL-10 and blockade of the protective factors needed to control the mycobacterial infection (Fig. 2 ).
Blood transcriptomics reveal heterogeneity in lTBI and TB progression
A longitudinal transcriptomics analysis of cynomolgus macaques infected with M. tuberculosis 47 , which recapitulate the spectrum of The majority of the exposed people will remain asymptomatic, with the following possible scenarios: they will remain uninfected or eliminate the bacteria (purple); they will become infected but control the bacteria either by innate immune responses (purple) or by a T cell response specific to M. tuberculosis antigen, as detected by IGRA (gradation from purple to black); or they will develop subclinical TB and show pulmonary abnormalities, as detected by advanced radiographic approaches, and a transient blood signature (black). A small proportion of exposed people will progress to active TB (red) and further represent a spectrum of infection states on the basis of the M. tuberculosis load (as measured by a smear test of sputum (indicative of high bacterial load); by culture of M. tuberculosis or nucleic-acid-amplification test; or, if sputum produces a negative result, by analysis of bronchoalveolar lavage (BAL) fluid, where possible (indicative of a lower bacterial load)) and might manifest various degrees of symptoms (intensity of red shading). *, usually positive; + /-, can be positive or negative. The arrow along the right margin indicates an increase in the load and symptoms (low at the bottom and high at the top). Adapted from ref. 3 . , has reported increased transcriptional activity of genes encoding molecules in innate and adaptive pathways early during infection, including an interferon signature. The blood transcriptome signature correlated with lung inflammation, as measured by positron-emission and computed tomography at early time points after infection, and with the extent of disease 47, 72 . Blood transcriptomics analyses of people with latent TB who have pulmonary abnormalities suggestive of subclinical active disease and are co-infected with HIV have identified an over-abundance of the classical complement pathway and Fcγ receptor 1, and increased amounts of circulating immunocomplexes in people with evidence of subclinical disease 9, 73 . The increased expression of classical complement components in TB might be a response to increased production of immunocomplexes at the site of disease and might allow inhibition of the precipitation of immunocomplexes by the complement component C1q to minimize lung damage 9, 73 . An increase in complement components was also observed in a subset of patients within a cohort of 6,363 healthy adolescents who were followed for 24 months or more 35, 74 . People who ultimately developed microbiologically confirmed TB disease more than 6 months after enrollment (n = 44) 35 were compared with 106 control subjects (matched for age, sex, ethnicity, school and prior history of TB) who remained healthy during 2 years of follow-up. Transcriptomics analysis of blood collected every 6 months until diagnosis showed a sequential modulation of immunological processes that preceded the manifestation of TB and subsequent clinical diagnosis 35 . Signaling via type I and II interferons, as well as the increased expression of genes encoding molecules involved in the complement cascade, were observed up to 18 months before diagnosis, while changes in the expression of other genes encoding inflammatory molecules were observed closer to the manifestation of disease 35 . However, re-infection is prevalent in countries with a high incidence of TB [75] [76] [77] [78] [79] [80] [81] [82] , which makes it challenging to separate the processes that arise as a result of re-activation of infection from those caused by re-infection. Independent re-analysis of the same dataset has suggested heterogeneity in the expression of the genes encoding complement components and the Fcγ -receptor at an individual level 73 . Collectively, these studies suggest that there might be a state consistent with subclinical TB that consists of a specific increase in the expression of interferon-response genes and activation of the complement cascade, which can be revealed in the blood of people with no other signs of disease 35, 73 . Both studies 35, 73 restricted their analysis to IGRA + LTBI, with the assumption that IGRA -people do not have latent infection. IGRAs have an overall sensitivity of approximately 85% in microbiologically confirmed active TB, which indicates that a portion of latent infections will be missed through the use of this test alone 83 . Although settings with a high incidence of TB have often been referred to as 'real-world TB' , TB in settings with a low incidence remains a burden on public health, and both settings need to be addressed in order to eradicate TB. There are clear differences between these settings in the priorities, needs and goals for the control of TB (Supplementary Table 1 ). Settings with a high burden of TB and low income have fragile health-service frameworks with scarce resources and limited availability of either standard diagnostics or advanced diagnostics, which allows onward transmission of infection that perpetuates poor control of TB. In settings of very high incidence, consideration of TB-prevention strategies will be complicated by the high risk of re-infection. Settings with a low burden of TB and high income have well-resourced health-service frameworks and extensive access to diagnostic tools. A biomarker sampled from an easily accessible part of the body that identifies latent infection at high risk of TB progression with sensitivity and specificity greater than that of IGRAs and the tuberculin skin test would greatly advance earlier diagnosis of TB. Biomarkers of TB risk might best be validated reliably in settings with a low incidence of TB in which the risk of re-infection is low, unless study design in countries with a high burden verifies that disease did not arise from re-infection, by comparison of the M. tuberculosis sequence from the index TB case with that of the LTBI contact who seemingly undergoes reactivation of TB.
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A proportion of people with LTBI across cohorts from London, South Africa 24, 39 and Leicester 39 clustered with patients with active TB on the basis of their transcriptional blood signature and exhibited an interferon-inducible signature similar to that observed in patients with active TB; such people have been called 'LTBI outliers' 24, 39 . Modular analysis has indicated that the molecules encoded by genes co-expressed in LTBI outliers and patients with active TB represent biological processes linked to the interferon response, complement system, myeloid and pattern-recognition receptors 39 . In addition, the reduced expression of IFNG and TBX21 in these LTBI outliers suggests evolution of the host response toward that of active TB 39 . Because these LTBI outliers represent static instances of latent infection, the transcriptional profiles of people recently exposed to M. tuberculosis through contact with patients with active TB who either remained healthy (n = 31) or developed active TB disease (n = 9) were evaluated over time in Leicester, a setting with minimal risk of re-infection. Most IGRA -people who remained healthy showed few perturbations in their modular transcriptional signature over time. A proportion of the IGRA + people had profiles similar to those observed in TB, although in most cases this was transient 39 . In contrast, a modular signature similar to that of active TB was observed in the majority (67%) of those who progressed to TB before diagnosis 39 . The blood transcriptome thus provides a sensitive approach with which to characterize between-subject . It also appears that early events after exposure, measured as patterns of dynamic change in the transcriptional immune response, might influence the fate of infection 39, 47 .
Host transcriptional gene signatures in the diagnosis of TB
A key advantage of identification of gene signatures from the blood transcriptome as a biomarker for TB progression is the ease of blood testing. This is relevant for groups in which microbiological diagnosis is constrained by a limited ability to acquire samples, including pulmonary TB associated with little or no sputum production, typically seen in early disease, before cavitation; extra-pulmonary TB, in which microbiological diagnosis requires examination of samples from the infected tissue site through invasive procedures; pediatric TB, which is paucibacillary and minimally productive of sputum; and HIV-associated TB, in which pathology that leads to sputum production is diminished.
The use of transcriptomics as a diagnostic tool specific for TB relies on the ability to identify commonalities and differences between TB and other infectious conditions and diseases in terms of the host response 18, 30, 39, [84] [85] [86] . Although patients with TB and those with sarcoidosis show a big overlap in their blood transcriptome, sharing interferon signaling and proinflammatory pathways 28, 30, 87 , a subset of genes that are regulated differentially can be used to discriminate between the two pathologies, as well as between TB and lung cancer or pneumonia 27, 29 . The increased expression of two sets of interferon-inducible genes is also shared by TB and viral infection, albeit at different levels of enrichment 39 . While enrichment for the expression of genes encoding components of the complement system and myeloid is greater in TB, expression of the interferon-inducible gene set that includes genes encoding pattern-recognition receptors and virus-induced genes is higher in viral infection 39 . Conversely, perturbations in cell proliferation, metabolism and hematopoiesis have been observed during viral infection but not in TB 39 . The identification of gene signatures that could be used as diagnostic biomarkers for TB requires the definition of a small gene set with high diagnostic accuracy in multiplex testing. Currently there is no consensus on these diagnostic signatures. Studies have reported distinct sets of genes, each identified through the use of standard machine-learning algorithms, most with similar performance 34, [88] [89] [90] [91] [92] [93] ( Table 2 and Supplementary Table 2 ). These signatures cannot discriminate between TB and diseases such as pneumonia 94, 95 , and they also identify acute viral infections 39 . This is a potential problem in children and some adults, in whom primary TB can present with clinical and radiological features often indistinguishable from those of respiratory viral illness 96, 97 . In people co-infected with HIV, TB frequently presents as a rapid onset of non-specific respiratory and systemic illness. Tuberculous meningitis, for which an improved outcome critically depends on early intervention, requires an average of three visits by a healthcare practitioner before it is even suspected 98 . In the context of an LTBI-screening program, the prevalence of intercurrent viral illness at the time of testing might be important and would represent a confounding factor, which would diminish the specificity of existing gene signatures for this purpose.
A 20-gene signature composed of genes whose expression was perturbed in TB but not in influenza was identified to circumvent the problems noted above, on the basis of a modular approach (Fig. 3) followed by machine-learning algorithms 39 . This 20-gene signature 'captures' multiple biological pathways and is able to discriminate, albeit with lower sensitivity than that of less-discriminant signatures, between TB and LTBI (Supplementary Table 2 ) and, notably, does not detect influenza, as an example of viral infections 39 , and provides a proof of principle for new approaches to identify signatures with lower expression ('reduced signatures'). The 20-gene signature was detected in the majority of people who progressed to TB in the Leicester cohort weeks or even months before clinical diagnosis 39 , but expression of this signature was only minimally enriched in most IGRA -contacts and was only transiently enriched in the IGRA + group that did not progress to disease. Other signatures with a low number of genes have been identified in asymptomatic people with LTBI and patients with subclinical TB who progressed to active TB 74, 99 (Table 2 and Supplementary Table 2) . A 16-gene risk signature was evident up to 6 months before clinical presentation with TB disease in a South African adolescent cohort 74 . However, this 16-gene signature inadvertently also detected patients with influenza versus healthy control subjects with high specificity and sensitivity 39 . In multiple sub-Saharan African cohorts of TB-exposed, HIV-negative contacts, a four-gene transcript signature identified people at high-risk of developing TB up to 2 years before the onset of disease 99 . The findings reported above suggest that there might be a tradeoff in achieving a diagnostic TB signature with both a high sensitivity against LTBI and high specificity against other diseases, and that alternative and complementary approaches beyond machine-learning algorithms should be considered for gene-signature selection. For example, applying a modular approach to obtain information about gene-expression changes across the global immune response that are observed in TB but not in LTBI or other potentially confounding diseases (Fig. 3) , followed by machine-learning algorithms, to select the most-discriminant genes across multiple differentially expressed modules, might allow the identification of a more-specific gene signature with a low number of genes. Pooling such a signature with a second signature characterized by high sensitivity for the detection of TB and applying combined yet discriminatory algorithms could allow the development of a test with which to diagnose TB with greater confidence. The additional use of gene sets that Modular approaches can be used to tease out subtle differences between TB and other diseases and infections through the profiling of blood from patients by transcriptomics approaches, such as RNA sequencing, to capture the entire transcriptome. Each gene within the transcriptome is expressed at a particular level across each individual sample, and genes encoding molecules involved in similar biological pathways are coordinately expressed. These groups of coordinately expressed genes constitute individual modules that represent discrete biological pathways and can be identified through the use of unbiased approaches such as weighted gene co-expression network analysis. Perturbations in gene expression as a response to infection with M. tuberculosis or other pathogens can be measured within each module of co-expressed genes relative to the expression of those genes in healthy control subjects. Through the use of such an approach, modular signatures can be identified for TB and other infections and diseases to provide information on the immune response, and this information can also be used to identify signatures with small gene sets that are specific to TB, to identify biomarkers for diagnosis. might provide added clinical utility for determining optimal treatment duration. The diminished expression of the blood transcriptome signature observed during successful treatment of TB could also help in monitoring the response to treatment and in the development of new drugs, given that the current tests for monitoring drug efficacy, such as the early bactericidal assays and 2-month sputum conversion, both are time-consuming and lack specificity, even when sputum can be obtained 100 . Such diagnostic biomarkers will need to be carefully tested in a multitude of TB cohorts from distinct geographical locations and will need to be optimized for specificity through the use of cohorts with other infections. New molecular platforms with greater capacity for multiplexing could be of help in facilitating the use of such tests in the clinic. Furthermore, it is anticipated that different contexts, goals and clinical applications in countries with a high incidence and low income or those with a low incidence and high income (Supplementary Table 1 ) will dictate the use of a transcriptomics-based diagnostic or prognostic tool, in addition to a tool for monitoring drug treatment.
Conclusions and future perspectives
There is still limited understanding of the complete spectrum of infectious states evident in people latently infected with M. tuberculosis. Highly sensitive radiographic imaging, together with blood transcriptome signatures, has revealed the heterogeneity of latent TB in both humans and non-human primate models. However, the events that determine whether an exposed person will control the infection or go on to develop TB are unknown. Understanding the host response in the lungs directly after exposure to M. tuberculosis is critical for determining how this might influence the outcome of infection. This could be achieved through the use of transcriptomic and complementary immunological approaches in well-defined and carefully curated clinical cohorts, with longitudinal profiling of blood samples as well as lung samples (for example, bronchoalveolar lavage fluid) from people exposed to TB. This will advance the knowledge of the local host immune response involved in the control of infection or progression to disease.
Transcriptomic approaches have also shown promise in the development of biomarkers for the diagnosis and prognosis of TB and for the monitoring of drug treatment. Biomarker signatures for clinical use would need to be 'downsized' to facilitate a multiplextype test, would need to be rapid and automated, with a turnaround time of 2-3 hours, and would need to be inexpensive, to be feasible for implementation testing in a clinical or bedside setting. This would facilitate the effective and early treatment that is essential for the eradication of TB. 
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